Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

3D printing is a manufacturing game-changer

Calling all carnivores: ever thought about getting a meat printer? Of hand-crafting delectable beef steaks at home from plant proteins, that have the same texture, appearance and flavor as real meat, only without the distasteful killing part? 3D-printed steaks and chicken ...
Richard (Rick) Mills | November 15, 2019 |

A Revolution in Healthcare. A Transformative Investment Opportunity.

(Click image to play video) While the global COVID-19 pandemic has wreaked havoc on health and humanity over the past 12-month-plus, it has also invited a host of creative and innovative solutions to meet the needs of people who require a medical attention witho...
Dave Jackson | April 9, 2021 |

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

The Power of Palladium

The StockTalk Podcast Hosts Expert Panel on Palladium & PGMs Palladium is a rare, precious metal – one of the six platinum group metals (PGMs). Its very name conjures up exotic images of a glistening, space-age metal with a price-tag that matches its scarcity. ...
Dave Jackson | October 31, 2019 |

Top Gold Stocks – January 2020

Gold is the most popular precious metal to invest in. Gold is what’s known as a “safe haven asset” where investors buy-in as a way of diversifying risk, especially through futures contracts and derivatives. Like other markets, gold is subj...
Stockhouse Editorial | July 24, 2019 |

Hemostemix Founder: A Man with a Compassionate Heart

The Canadian stem cell company Hemostemix Inc. ( TSX-V: HEM , OTC: HMTXF ) was founded by a man who truly had a compassionate heart and a clear intent to establish a breakthrough in heart disease using the same technology that saved his life. Roger Bergersen, who train...
Featured Submission | December 14, 2020 |

We Should Let the Banks Burn Down

Bob Moriarty of 321 Gold explains why he believes banks should be allowed to fail. In later 2008 during what is now referred to as the Great Financial Crisis, government and financial managers had an opportunity to reset a badly out of balance banking system....
Streetwise Reports | August 7, 2019 |

Stemline Shares Take Off on $677 Million Buyout Offer by Global Pharmaceutical Firm

Shares of Stemline Therapeutics traded 150% higher after the company reported that it has entered into a definitive agreement to be acquired by Italy's Menarini Group in a deal valued at up to $677 million. Stemline Therapeutics Inc. (STML:NASDAQ) , which is...
Streetwise Reports | May 5, 2020 |

Analyst: G1 Minimizes the Carnage of Chemotherapy

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy ...
Streetwise Reports | July 2, 2020 |

AI & Humor in the Workplace … A Laughing Matter?

We have all worried about “robots taking our jobs”, but working in a creative field, I’ve always had a high-and-mighty belief that no mere machine could do what I do … until they could. Running a certain set of parameters through an ar...
According to published reports | September 1, 2021 |
1 2